Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) had its price objective decreased by analysts at Wells Fargo & Company from $8.00 to $6.00 in a report issued on Thursday,Benzinga reports. The firm currently has an "equal weight" rating on the stock. Wells Fargo & Company's price objective suggests a potential upside of 261.45% from the stock's previous close.
A number of other research firms have also weighed in on ZNTL. HC Wainwright dropped their price target on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday. Wedbush restated a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. UBS Group decreased their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday. Finally, Guggenheim reduced their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Zentalis Pharmaceuticals has a consensus rating of "Hold" and an average price target of $8.24.
Get Our Latest Report on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Stock Down 12.2 %
Shares of ZNTL traded down $0.23 during midday trading on Thursday, hitting $1.66. The company's stock had a trading volume of 3,656,997 shares, compared to its average volume of 2,910,479. Zentalis Pharmaceuticals has a one year low of $1.66 and a one year high of $18.07. The stock has a market capitalization of $118.29 million, a price-to-earnings ratio of -0.67 and a beta of 1.86. The company's fifty day simple moving average is $3.00 and its two-hundred day simple moving average is $3.30.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.36. On average, research analysts predict that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Paloma Partners Management Co purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at about $37,000. Aigen Investment Management LP bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at about $41,000. Capstone Investment Advisors LLC bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at about $48,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock worth $50,000 after purchasing an additional 5,333 shares during the period.
About Zentalis Pharmaceuticals
(
Get Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
